CLINICAL TRIALS PROFILE FOR INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
✉ Email this page to a colleague
All Clinical Trials for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00658099 ↗ | Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard® | Completed | Novo Nordisk A/S | 2007-11-01 | This trial is conducted in Europe. The aim of this observational study is to evaluate the change in weight in type 2 diabetes patients using Levemir® or Insulatard® under normal clinical practice conditions. | |
NCT00665808 ↗ | Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany | Completed | Novo Nordisk A/S | 2007-10-01 | This NON INTERVENTIONAL OBSERVATIONAL STUDY is conducted in Europe. The purpose of this NON INTERVENTIONAL OBSERVATIONAL STUDY is to primarily investigate treatment satisfaction when using Levemir® versus Protaphane® in combination with OADs in daily settings. | |
NCT01122979 ↗ | Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. | Completed | Sanofi | Phase 4 | 2010-07-01 | Primary Objective: >To obtain an estimation for both treatment groups of the proportion of patients that reach the target of HbA1c <= 7% without confirmed nocturnal hypoglycaemia in each treatment group. Secondary Objectives: - Glycemic control, measured by HbA1c and FPG (fasting plasma glucose) at baseline and after each period of treatment. - Incidence of confirmed symptomatic and nocturnal hypoglycemia. - Incidence of confirmed severe hypoglycemia (< 36mg/dL or need of help to recover). >Weight variation for each period of treatment. - Creatinine clearance at baseline and after each period of treatment. - Overall safety: Incidence of adverse events. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human
Condition Name
Clinical Trial Locations for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human
Trials by Country
Clinical Trial Progress for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human
Clinical Trial Phase
Clinical Trial Sponsors for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human
Sponsor Name
Sponsor Name for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human | |
Sponsor | Trials |
Profil Institut für Stoffwechselforschung GmbH | 2 |
Julphar Gulf Pharmaceutical Industries | 2 |
Novo Nordisk A/S | 2 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |